A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef
Research payments
$2,811,821
Through program year 2024, $2,811,821 in research payments was reported against A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef, across 621 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $108,825 | 21 |
| 2023 | Research | $257,798 | 97 |
| 2022 | Research | $502,356 | 123 |
| 2021 | Research | $568,481 | 122 |
| 2020 | Research | $549,668 | 117 |
| 2019 | Research | $824,693 | 141 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Princy Kumar Washington, DC Named on 41 payments
- Gary Richmond Fort Lauderdale, FL Named on 23 payments
- Susan Swindells Omaha, NE Named on 23 payments
- Cheryl Newman Augusta, GA Named on 22 payments
- Franco Felizarta Bakersfield, CA Named on 19 payments
- Anthony Scarsella Beverly Hills, CA Named on 17 payments
- Debbie Hagins Savannah, GA Named on 15 payments
- Anthony Mills Los Angeles, CA Named on 14 payments
- Eric Meissner Charleston, SC Named on 14 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.